What Is Orphan Drug Supply?
Orphan drugs are medicines developed to treat rare diseases — conditions that affect fewer than 1 in 2,000 people in the European Union or fewer than 200,000 patients in the United States. Because of the small patient populations involved, these medicines often receive special regulatory designation from bodies such as the EMA, FDA, or PMDA to incentivise their development and bring them to market.
GNH India sources orphan drugs directly from manufacturers holding orphan designation from EMA, FDA, or PMDA, or from their authorised distributors. Because orphan drugs frequently have limited or no local registration outside their primary markets, patients in most countries must access them through alternative regulatory pathways, including:
- Named Patient Supply (NPS) programs
- Parallel import from countries where the medicine is approved
- Early access or compassionate use frameworks
GNH India manages the full regulatory and logistics process — from initial feasibility assessment and import permit coordination to GDP-compliant cold-chain delivery — ensuring patients with rare conditions receive the therapies they need, wherever they are in the world.
Our Orphan Drug Supply Process
Our end-to-end orphan drug supply service is designed to be transparent, efficient, and patient-centric, combining regulatory expertise with specialist rare disease logistics.
1. Clinical Verification:
The treating physician submits the patient's diagnosis, a valid prescription, and a medical necessity statement confirming that no approved treatment alternative is available locally. This documentation forms the basis of the regulatory submission.
2. Regulatory Feasibility:
Our regulatory team confirms the appropriate import pathway — Named Patient Supply, parallel import, or early access — for the destination country, identifies required permits and licences, and advises on timelines and documentation requirements.
3. Manufacturer Sourcing:
We procure the orphan drug from EMA/FDA orphan-designated manufacturers or their authorised distributors, with full batch traceability and certificate-of-analysis documentation to ensure authenticity and quality.
4. Cold-Chain Logistics:
Many orphan biologics require temperature-controlled storage and transport (typically 2–8°C). We manage GDP-compliant cold-chain logistics from the point of origin to the patient's bedside, using validated packaging and real-time temperature monitoring throughout.
5. Delivery & Follow-up:
Secure delivery is made to the designated hospital pharmacy, clinic, or authorised healthcare facility, followed by post-supply pharmacovigilance support and ongoing coordination for continued or repeat therapy where required.
Why GNH India for Orphan Drug Supply?
- 20+ years supplying rare and specialty medicines to 180+ countries across North America, Europe, the Middle East, Asia, and Africa.
- Direct relationships with orphan drug manufacturers and authorised distributors holding EMA, FDA, and PMDA designations.
- Dedicated rare disease regulatory team with expertise in EMA, FDA, CDSCO, and PMDA pathways, including Named Patient Supply and compassionate use frameworks.
- Full cold-chain and GDP-compliant logistics for temperature-sensitive biologics, with real-time monitoring and validated packaging.
- End-to-end case management from first enquiry to ongoing supply continuity, with a single point of contact for each patient case.
- ISO 9001:2015 and WHO-GSDP certified operations, ensuring international standards of quality and compliance at every step.
Regulatory recognitions
Quality You Can Trust
Our internationally recognized certifications underscore our commitment to safety, quality, and excellence in pharmaceutical distribution.
